혈액 배양 검사 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 방법별, 최종 용도별, 기술별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Blood Culture Test Market Growth & Trends:

The global blood culture test market size is expected to reach USD 13.23 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 12.3% from 2024 to 2030. Owing to the increasing incidence of bloodstream infections as well as infectious diseases. Rising demand for advanced diagnostic techniques for the diagnosis of infectious diseases, such as sepsis, is also projected to drive growth. Recently, a substantial number of market players are focusing on the development of advanced tests with an aim to improve the efficiency of overall diagnostic procedures. Thus, many manufacturing companies are focusing on the development of advanced diagnostic instruments and consumables.

For instance, in May 2022, Cepheid confirmed that its Xpert Xpress CoV-2plus, a quick molecular diagnostic test for the identification of the infectious virus that causes COVID-19, has obtained the CE mark. Xpert Xpress CoV-2plus unites Xpert Xpress CoV-2/Flu/RSV plus as well as other PCRplus respiratory assessments in Cepheid's diverse range of rapid, reliable, and implementable respiratory results. Such developments are likely to have a positive impact on the growth of the market during the forecast period. The introduction of various government initiatives pertaining to the prevention and control of infections is likely to propel the demand for blood culture tests.

Moreover, the authorities are also focusing on the implementation of strict guidelines to maintain the quality of diagnostics. For instance, in May 2022, CLSI released new National Blood Culture guidelines to prevent and reduce blood culture contaminations. Such regulations are also projected to accelerate the demand by 2030. A massive rise in the number of patients with COVID-19 infection throughout the world resulted in a significant increase in blood culture utilization, which greatly impacted the demand for automated instruments. For instance, in February 2022, Becton, Dickinson, and Company collaborated with ReturnSafe, an all-in-one software application for COVID-19 employee health, well-being, and adherence, to incorporate the BD Verito At-Home COVID-19 Test kits.

This consolidated solution, which uses the ReturnSafe and BD Veritor at-home COVID-19 Test, enables convenient and cost-effective administration of an enterprise's overall population. Key players are focusing on collaborations for the introduction of novel technologies. For instance, in September 2022, OpGen announced a strategic collaboration with FIND for rapid diagnosis of antimicrobial resistance (AMR) with the help of blood culture. Such developments are estimated to offer a favorable environment for market growth.

Blood Culture Test Market Report Highlights:

• The conventional technique segment captured the largest share in 2023 due to higher applications of this method in hospitals, individual clinical laboratories, as well as pathology laboratories
• The consumables segment accounted for the largest revenue share in 2023 owing to the increased adoption of blood culture tests across all the applications
• The automated systems segmentis anticipated to register the fastest CAGR from 2024 to 2030 owing to the increasing demand for technologically advanced diagnostic systems, improved accuracy, and minimal turn-around time
• The molecular technology segment is anticipated to grow at the highest CAGR over the forecast period owing to the high demand for innovative products by hospitals and laboratories for the diagnosis of infectious diseases
• The bacterial infections segment held the maximum share in 2023 owing to the high prevalence of bacterial infections and the adoption of these tests for bacterial disease diagnosis due to its proven success rate
• The reference laboratories segment is anticipated to grow at the highest CAGR during the forecast period as there is a rise in outsourcing of blood tests by hospitals to reference laboratories
• North America accounted for the highest revenue share in 2023 owing to massive investments in research & development

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation And Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Technique Segment
    • 1.1.1.2. Product Segment
    • 1.1.1.3. Application Segment
    • 1.1.4.4. technology Segment
    • 1.1.4.5. end Use Segment
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Technological Advancements In Products
  • 3.4.2. Rising Prevalence Of Infectious Diseases and Bloodstream Infections
  • 3.4.3. High Demand For Advanced Diagnostic Techniques
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost Of Automated Instruments
  • 3.5.2. Stringent Regulatory Framework
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
• 3.7. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Blood Culture Tests Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
  • 4.2.2. Instruments Market, by Type
    • 4.2.2.1. Bacterial Infections
    • 4.2.2.1.1. Bacterial Infections Market, 2018 - 2030 (USD Billion)
    • 4.2.2.2. Fungal Infections
    • 4.2.2.2.1. Fungal Infections Market, 2018 - 2030 (USD Billion)
    • 4.2.2.3. Mycobacterial Infections
    • 4.2.2.3.1. Mycobacterial Infections Market, 2018 - 2030 (USD Billion)
  • 4.2.3. Instrument Market, by Components
    • 4.2.3.1. Laboratory Equipment
    • 4.2.3.1.1. Laboratory Equipment Market, 2018 - 2030 (USD Billion)
    • 4.2.3.1.1.1. Incubators
    • 4.2.3.1.1.1.1. Incubators Market, 2018 - 2030 (USD Billion)
    • 4.2.3.1.1.2. Colony Counters
    • 4.2.3.1.1.2.1. Colony Counters Market, 2018 - 2030 (USD Billion)
    • 4.2.3.1.1.3. Microscopes
    • 4.2.3.1.1.3.1. Microscopes Market, 2018 - 2030 (USD Billion)
    • 4.2.3.1.1.4. Gram Stainers
    • 4.2.3.1.1.4.1. Gram Stainers Market, 2018 - 2030 (USD Billion)
    • 4.2.3.2. Automated Blood Culture Systems
    • 4.2.3.2.1. Automated blood culture systems Market, 2018 - 2030 (USD Billion)
• 4.3. Consumables
  • 4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
  • 4.3.2. Consumables Market, by Type
    • 4.3.2.1. Bacterial Infections
    • 4.3.2.1.1. Bacterial Infections Market, 2018 - 2030 (USD Billion)
    • 4.3.2.2. Fungal Infections
    • 4.3.2.2.1. Fungal Infections Market, 2018 - 2030 (USD Billion)
    • 4.3.2.3. Mycobacterial Infections
    • 4.3.2.3.1. Mycobacterial Infections Market, 2018 - 2030 (USD Billion)
  • 4.3.3. Consumables Market, by Components
    • 4.3.3.1. Blood Culture Media
    • 4.3.3.1.1. Blood Culture Media Market, 2018 - 2030 (USD Billion)
    • 4.3.3.1.1.1. Aerobic blood culture media
    • 4.3.3.1.1.1.1. Aerobic blood culture media Market, 2018 - 2030 (USD Billion)
    • 4.3.3.1.1.2. Anaerobic blood culture media
    • 4.3.3.1.1.2.1. Anaerobic blood culture media Market, 2018 - 2030 (USD Billion)
    • 4.3.3.1.1.3. Fungi/yeast blood culture media
    • 4.3.3.1.1.3.1. Fungi/yeast blood culture media, 2018 - 2030 (USD Billion)
    • 4.3.3.1.1.4. Others blood culture media
    • 4.3.3.1.1.4.1. Others blood culture media Market, 2018 - 2030 (USD Billion)
    • 4.3.3.2. Assay, Kits, and Reagents
    • 4.3.3.2.1. Assay, kits, and reagents Market, 2018 - 2030 (USD Billion)
    • 4.3.3.3. Blood culture accessories
    • 4.3.3.3.1. Blood Culture Accessories Market, 2018 - 2030 (USD Billion)
• 4.4. Software and Services
  • 4.4.1. Bacterial Infections
    • 4.4.1.1. Bacterial Infections Market, 2018 - 2030 (USD Billion)
  • 4.4.2. Fungal Infections
    • 4.4.2.1. Fungal Infections Market, 2018 - 2030 (USD Billion)
  • 4.4.3. Mycobacterial Infections
    • 4.4.3.1. Mycobacterial Infections Market, 2018 - 2030 (USD Billion)

Chapter 5. Technology Business Analysis

• 5.1. Blood Culture Tests Market: Technology Movement Analysis
• 5.2. Culture-based Technology
  • 5.2.1. Culture-based Technology Market, 2018 - 2030 (USD Billion)
• 5.3. Molecular Technology
  • 5.3.1. Molecular Technology Market, 2018 - 2030 (USD Billion)
    • 5.3.1.1. PCR
    • 5.3.1.1.1. PCR Market, 2018 - 2030 (USD Billion)
    • 5.3.1.2. Microarray
    • 5.3.1.2.1. Microarray Market, 2018 - 2030 (USD Billion)
    • 5.3.1.3. PNA-FISH
    • 5.3.1.3.1. PNA-FISH Market, 2018 - 2030 (USD Billion)
• 5.4. Proteomic Technology
  • 5.4.1. Proteomic Technology Market, 2018 - 2030 (USD Billion)

Chapter 6. Technique Business Analysis

• 6.1. Blood Culture Tests Market: Technique Movement Analysis
• 6.2. Conventional
  • 6.2.1. Conventional Technique Market, 2018 - 2030 (USD Billion)
• 6.3. Automated
  • 6.3.1. Automated Technique Market, 2018 - 2030 (USD Billion)

Chapter 7. Application Business Analysis

• 7.1. Blood Culture Tests Market: Application Movement Analysis
• 7.2. Bacterial Infections
  • 7.2.1. Bacterial Infections Market, 2018 - 2030 (USD Billion)
• 7.3. Fungal Infections
  • 7.3.1. Fungal Infections Market, 2018 - 2030 (USD Billion)
• 7.4. Mycobacterial infections
  • 7.4.1. Mycobacterial infections Market, 2018 - 2030 (USD Billion)

Chapter 8. End-use Business Analysis

• 8.1. Blood Culture Tests Market: End-use Movement Analysis
• 8.2. Hospital Laboratories
  • 8.2.1. Hospital Laboratories Market, 2018 - 2030 (USD Billion)
• 8.3. Reference Laboratories
  • 8.3.1. Reference Laboratories Market, 2018 - 2030 (USD Billion)
• 8.4. Others
  • 8.4.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 9. Regional Business Analysis

• 9.1. Blood Culture Tests Market Share By Region, 2022 & 2030
• 9.2. North America
  • 9.2.1. SWOT Analysis
  • 9.2.2. North America Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.2.3. U.S.
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Target Disease Prevalence
    • 9.2.3.3. Competitive Scenario
    • 9.2.3.4. Regulatory Framework
    • 9.2.3.5. Reimbursement Scenario
    • 9.2.3.6. U.S. Blood Culture Tests Market, 2018 - 2030 (USD Million)
  • 9.2.4. Canada
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Target Disease Prevalence
    • 9.2.4.3. Competitive Scenario
    • 9.2.4.4. Regulatory Framework
    • 9.2.4.5. Reimbursement Scenario
    • 9.2.4.6. Canada Blood Culture Tests Market, 2018 - 2030 (USD Billion)
• 9.3. Europe
  • 9.3.1. SWOT Analysis
  • 9.3.2. Europe Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Target Disease Prevalence
    • 9.3.3.3. Competitive Scenario
    • 9.3.3.4. Regulatory Framework
    • 9.3.3.5. Reimbursement Scenario
    • 9.3.3.6. Germany Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.4. UK
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Target Disease Prevalence
    • 9.3.4.3. Competitive Scenario
    • 9.3.4.4. Regulatory Framework
    • 9.3.4.5. Reimbursement Scenario
    • 9.3.4.6. UK Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.5. France
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Target Disease Prevalence
    • 9.3.5.3. Competitive Scenario
    • 9.3.5.4. Regulatory Framework
    • 9.3.5.5. Reimbursement Scenario
    • 9.3.5.6. France Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.6. Italy
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Target Disease Prevalence
    • 9.3.6.3. Competitive Scenario
    • 9.3.6.4. Regulatory Framework
    • 9.3.6.5. Reimbursement Scenario
    • 9.3.6.6. Italy Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.7. Spain
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Target Disease Prevalence
    • 9.3.7.3. Competitive Scenario
    • 9.3.7.4. Regulatory Framework
    • 9.3.7.5. Reimbursement Scenario
    • 9.3.7.6. Spain Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.8. Denmark
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Target Disease Prevalence
    • 9.3.8.3. Competitive Scenario
    • 9.3.8.4. Regulatory Framework
    • 9.3.8.5. Reimbursement Scenario
    • 9.3.8.6. Denmark Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.9. Sweden
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Target Disease Prevalence
    • 9.3.9.3. Competitive Scenario
    • 9.3.9.4. Regulatory Framework
    • 9.3.9.5. Reimbursement Scenario
    • 9.3.9.6. Sweden Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.3.10. Norway
    • 9.3.10.1. Key Country Dynamics
    • 9.3.10.2. Target Disease Prevalence
    • 9.3.10.3. Competitive Scenario
    • 9.3.10.4. Regulatory Framework
    • 9.3.10.5. Reimbursement Scenario
    • 9.3.10.6. Norway Blood Culture Tests Market, 2018 - 2030 (USD Billion)
• 9.4. Asia Pacific
  • 9.4.1. SWOT Analysis
  • 9.4.2. Asia Pacific Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.4.3. Japan
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Competitive Scenario
    • 9.4.3.4. Regulatory Framework
    • 9.4.3.5. Reimbursement Scenario
    • 9.4.3.6. Japan Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.4.4. China
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Competitive Scenario
    • 9.4.4.4. Regulatory Framework
    • 9.4.4.5. Reimbursement Scenario
    • 9.4.4.6. China Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.4.5. India
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Target Disease Prevalence
    • 9.4.5.3. Competitive Scenario
    • 9.4.5.4. Regulatory Framework
    • 9.4.5.5. Reimbursement Scenario
    • 9.4.5.6. India Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.4.6. South Korea
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Target Disease Prevalence
    • 9.4.6.3. Competitive Scenario
    • 9.4.6.4. Regulatory Framework
    • 9.4.6.5. Reimbursement Scenario
    • 9.4.6.6. South Korea Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.4.7. Australia
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Target Disease Prevalence
    • 9.4.7.3. Competitive Scenario
    • 9.4.7.4. Regulatory Framework
    • 9.4.7.5. Reimbursement Scenario
    • 9.4.7.6. Australia Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.4.8. Thailand
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Target Disease Prevalence
    • 9.4.8.3. Competitive Scenario
    • 9.4.8.4. Regulatory Framework
    • 9.4.8.5. Reimbursement Scenario
    • 9.4.8.6. Thailand Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.4.9. Singapore
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Target Disease Prevalence
    • 9.4.9.3. Competitive Scenario
    • 9.4.9.4. Regulatory Framework
    • 9.4.9.5. Reimbursement Scenario
    • 9.4.9.6. Singapore Blood Culture Tests Market, 2018 - 2030 (USD Billion)
• 9.5. Latin America
  • 9.5.1. SWOT Analysis
  • 9.5.2. Latin America Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.5.3. Brazil
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Competitive Scenario
    • 9.5.3.4. Regulatory Framework
    • 9.5.3.5. Reimbursement Scenario
    • 9.5.3.6. Brazil Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.5.4. Mexico
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Competitive Scenario
    • 9.5.4.4. Regulatory Framework
    • 9.5.4.5. Reimbursement Scenario
    • 9.5.4.6. Mexico Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.5.5. Argentina
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Competitive Scenario
    • 9.5.5.4. Regulatory Framework
    • 9.5.5.5. Reimbursement Scenario
    • 9.5.5.6. Argentina Blood Culture Tests Market, 2018 - 2030 (USD Billion)
• 9.6. MEA
  • 9.6.1. SWOT Analysis
  • 9.6.2. MEA Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.6.3. South Africa
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Competitive Scenario
    • 9.6.3.4. Regulatory Framework
    • 9.6.3.5. Reimbursement Scenario
    • 9.6.3.6. South Africa Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.6.4. Saudi Arabia
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Competitive Scenario
    • 9.6.4.4. Regulatory Framework
    • 9.6.4.5. Reimbursement Scenario
    • 9.6.4.6. Saudi Arabia Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.6.5. UAE
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Competitive Scenario
    • 9.6.5.4. Regulatory Framework
    • 9.6.5.5. Reimbursement Scenario
    • 9.6.5.6. UAE Blood Culture Tests Market, 2018 - 2030 (USD Billion)
  • 9.6.6. Kuwait
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Target Disease Prevalence
    • 9.6.6.3. Competitive Scenario
    • 9.6.6.4. Regulatory Framework
    • 9.6.6.5. Reimbursement Scenario
    • 9.6.6.6. Kuwait Blood Culture Tests Market, 2018 - 2030 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Company Categorization
• 10.2. Strategy Mapping
  • 10.2.1. New Product Launch
  • 10.2.2. Partnerships
  • 10.2.3. Acquisition
  • 10.2.4. Collaboration
  • 10.2.5. Funding
• 10.3. Key Company Market Share Analysis, 2022
• 10.4. Company Profiles
  • 10.4.1. Thermo Fisher Scientific, Inc.
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic Initiatives
  • 10.4.2. Becton, Dickinson and Company
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic Initiatives
  • 10.4.3. bioMerieux SA
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic Initiatives
  • 10.4.4. Danaher
    • 10.4.4.1. Company overview
    • 10.4.4.2. Product benchmarking
    • 10.4.4.3. Strategic Initiatives
  • 10.4.5. Luminex Corporation
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic Initiatives
  • 10.4.6. Hoffmann-La Roche Ltd
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic Initiatives
  • 10.4.7. Bruker Corporation
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic Initiatives
  • 10.4.8. Abbott
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic Initiatives
  • 10.4.9. Abtek Biologicals Ltd
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic Initiatives
  • 10.4.10. Autobio Diagnostics Co., Ltd.
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic Initiatives